Evidence map›Paper›PMID 39330554›Full record

ArticleToxics2024

In Vitro Prediction of Skin-Sensitizing Potency Using the GARDskin Dose-Response Assay: A Simple Regression Approach.

Robin Gradin, Fleur Tourneix, Ulrika Mattson, Johan Andersson, Frédéric Amaral, Andy Forreryd, Nathalie Alépée, Henrik Johansson

Abstract read
In one paragraph

Article in Toxics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Robin GradinSenzagen AB, 22381 Lund, Sweden.ORCID 0000-0002-3339-1269
Fleur TourneixL'Oréal, Research & Innovation, 93600 Aulnay-sous-Bois, France.
Ulrika MattsonSenzagen AB, 22381 Lund, Sweden.
Johan AnderssonSenzagen AB, 22381 Lund, Sweden.
Frédéric AmaralL'Oréal, Research & Innovation, 93600 Aulnay-sous-Bois, France.
Andy ForrerydSenzagen AB, 22381 Lund, Sweden.
Nathalie AlépéeL'Oréal, Research & Innovation, 93600 Aulnay-sous-Bois, France.
Henrik JohanssonSenzagen AB, 22381 Lund, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Toxicological assessments of skin sensitizers have progressed towards a higher reliance on non-animal methods. Current technological trends aim to extend the utility of non-animal methods to accurately characterize skin-sensitizing potency. The GARDskin Dose-Response assay has previously been described; it was shown that its main readout, cDV

Indexed as

GARDskin Dose–ResponseNAMpoint of departurequantitative risk assessmentsensitizing potency

Identifiers

PMID39330554
PMCPMC11435491

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.